Monday, December 14, 2015 2:58:59 PM
Start of Kevetrin advanced study in ovarian cancer.
Start of Brilacidin ABSSSI Phase 3
Start of Brilacidin for Ulcerative Proctitis proof of concept trial (phase 2)
Top line data on Kevetrin Phase 1 trial for advanced solid tumors
Top line data on Prurisol Phase 2 trial for chronic plaque psoriasis
Interim analysis for Brilacidin Phase 2 trial for Oral Mucositis
Start of Retinoblastoma program, formulation and toxicity studies
Additional ototoxicity studies with Brilacidin in different concentrations
Gram- negative and anti-fungal progress
Submission of grant application for study of Kevetrin in Pancreatic cancer with renowned hospital.
Let's take this as a "promissory note". If it all happens, we will be on the NASDAQ with $$$$. If little of it happens, well, then we will just have to re-evaluate things.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM